Longeveron® Announces World Health Organization Approval of “laromestrocel” as International Non-proprietary Name for Stem Cell Therapy Lomecel-B™
Portfolio Pulse from
Longeveron Inc. announced that the World Health Organization has approved 'laromestrocel' as the International Non-proprietary Name for its stem cell therapy Lomecel-B™, which is being evaluated for Alzheimer's disease and hypoplastic left heart syndrome.
February 18, 2025 | 2:45 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Longeveron Inc.'s stem cell therapy Lomecel-B™ has been granted the INN 'laromestrocel' by the WHO, a significant regulatory milestone that could enhance its marketability and recognition in the pharmaceutical industry.
The approval of an International Non-proprietary Name (INN) by the WHO is a crucial step in the development and commercialization of a pharmaceutical product. It provides a unique identifier for the therapy, facilitating its recognition and differentiation in the market. This can potentially lead to increased investor confidence and interest in Longeveron Inc., positively impacting its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100